MAPK3 and hepatocellular carcinoma: Furthermore, analyses of other Erk1/2 inhibitors reveal enhanced anti‐tumour efficacy when treatment initiates before tumour formation, contrasting with reduced inhibitory effects on established hepatocellular carcinoma xenografts [24].